The company's growth is based largely on proprietary guideline-supported methods of gene variant interpretation of data generated from next generation sequencing, backed by high-touch consultative service. 'Blueprint Genetics has developed a proven model for delivering highly specialized genetic insights that we believe we can scale to serve new patient populations with unmet clinical needs. The addition of Blueprint Genetics strengthens and extends the Quest value proposition in genetics, delivering on our Accelerate growth strategy and vision of a healthier world.'įounded in 2012, Blueprint Genetics grew rapidly, and now serves customers in over 70 countries. 'The great challenge with genetic testing is generating quality, actionable and broadly accessible insights from vast quantities of sequenced genetic data,' said Steve Rusckowski, Chairman, President and CEO, Quest Diagnostics. Financial terms of the transaction were not disclosed. Together, Quest and Blueprint Genetics will broaden access to actionable insights in genetic and rare diseases, improving patient care and pharmaceutical drug research and development. Blueprint Genetics is a leading specialty genetic testing company with deep expertise in gene variant interpretation based on next generation sequencing (NGS) and proprietary bioinformatics.

22, 2020 / PRNewswire/ - Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has acquired Blueprint Genetics in an all-cash equity transaction.

Blueprint gene